Latest News About Replimune Limited

Here’s a concise update on Replimune Limited based on the latest publicly available information.

• FDA status and recent developments: Replimune has faced significant regulatory hurdles around RP1, including a complete response letter (CRL) in mid-2025 regarding the RP1+BLA for advanced melanoma, with concerns centered on trial design and patient heterogeneity rather than safety. The company subsequently pursued a resubmission and engaged with the FDA to determine a path forward, including potential accelerated approval considerations.[2][4][8]

• 2026 milestones and activities: In 2026, Replimune has been active in presenting updates to investors and stakeholders, with references to an FDA PDUFA target action date for RP1 resubmission and ongoing commercial readiness activities, as well as updates on other programs (RP2 and IGnyte-related efforts).[1][5][6]

• Financial and strategic context: The company has disclosed cash positions and financing activities linked to advancing clinical programs and potential funding opportunities, while also indicating that the regulatory pathway (including accelerated approval possibilities) remains under evaluation.[3][5][1]

• Market and coverage: Coverage of Replimune spans investor-focused outlets and press releases, with occasional market updates tied to regulatory milestones and potential stock reactions around FDA decisions.[7][2][3]

If you’d like, I can summarize the key regulatory dates, pull the latest investor relations updates, or present a brief timeline of RP1 regulatory events with citations. I can also monitor for new FDA communications and company statements and provide alerts.